It has been reported that the expression of tissue transglutaminase (tTG) is associated with the expression of CD44 in ovarian cancer as well as in glioma-initiating cells, and that the genetic silencing or pharmaceutical inhibition of tTG in the latter is sufficient to impair cell proliferation and induce apoptosis in these cells [8, 35]. Here, TGM2 is linked to glioma.